179473-53-1

Basic information

• Product Name: 4-phenylindoline
• Synonyms: 4-phenylindoline
• CAS NO: 179473-53-1
• Molecular Weight: 195.264
• Mol File: 179473-53-1.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: 4-phenylindoline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-phenylindoline(179473-53-1)
• EPA Substance Registry System: 4-phenylindoline(179473-53-1)

Safety Data

• Hazardous Substances Data: 179473-53-1(Hazardous Substances Data)

Upstream product

• 35577-92-5 4-phenyl-1H-indole 
• 86626-38-2 4-bromo-2,3-dihydro-1H-indole 
• 98-80-6 phenylboronic acid 
• 52488-36-5 4-bromo-1H-indole 
• 107622-50-4 2-nitro-6-phenyltoluene 
• 55289-35-5 2-bromo-6-nitrotoluene 

Downstream Products

• 35577-92-5 4-phenyl-1H-indole 

Relevant articles and documents

Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold

Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy. Here, a novel series of indoline-containing compounds were developed, among which, A13 was identified as the most promising PD-1/PD-L1 pathway inhibitor. At the biochemical level, A13 demonstrated strong inhibition of the PD-1/PD-L1 interaction, with an IC50 of 132.8 nM. Notably, it exhibited outstanding immunoregulatory activity, and significantly elevated interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect. Therefore, A13 could be employed as a suitable lead compound for further design of non-peptide inhibitors targeting the PD-1/PD-L1 interaction. In addition, the preliminary structure-activity relationships of these new indoline compounds were investigated in this study, providing valuable information for future drug development.

Indoline compounds and preparing method and application thereof

The invention belongs to the technical field of medicines, and discloses indoline compounds having a general formula I in which substitutes R1, R2, R3, R4 and R5 are defined in the specification and apreparing method and application thereof. The indoline

Ring-fused compound, preparation method thereof and application of compound

The invention relates to a ring-fused compound or pharmaceutically acceptable salt thereof, ester, a steric isomer, a tautomer, a polymorphic substance, a solvate, a hydrate, a metabolite or prodrug or mixture of the materials, a medicine composition and medicine box product comprising the compound, a preparation method of the compound and an application of the compound to preparation of medicinesfor preventing or treating PD-1/PD-L1 related diseases.